A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
Title:
A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies
Author:
Das, Millie Padda, Sukhmani K. Frymoyer, Adam Molina, Julian Adjei, Alex Lensing, Janet L. Miles, Dale Sikic, Branimir I. Wakelee, Heather A.